Article
FDA threatens Ocugen with $10,000 fine for failing to report study results
Rating:
0.0
Views:
57
Likes:
1
Library:
1
A missing assignment from Ocugen's past has come back to haunt the clinical-stage biotech—and the issue could reveal deeper problems with the FDA's clinical trial oversight, one nonprofit contends. | The FDA has warned Ocugen that it could face a $10,000 fine unless it turns over results from an eye drug study that wrapped up in May 2019. The trial was looking at the safety and efficacy of brimonidine tartrate nanoemulsion in patients with dry eye disease.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value